Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10914881 | Molecular Oncology | 2014 | 11 Pages |
Abstract
This study shows that BCAR3, BCL2 and NAT1 in particular exhibit predictive promise regarding the efficacy of tamoxifen treatment in recurrent disease, in addition to the previously shown favorable outcome in the adjuvant setting.
Keywords
reverse transcriptase quantitative PCRIDCERBB2EMCDCISRT-qPCRPGRILCMFSER+Esr1PFsprogression-free survivalMetastasis-free survivalGene expressiontamoxifenEndocrine therapyBreast cancerEstrogen receptor-positiveDuctal carcinoma in situInfiltrating lobular carcinomaInfiltrating ductal carcinomaEstrogen receptorProgesterone receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Anieta M. Sieuwerts, Maria B. Lyng, Marion E. Meijer-van Gelder, Vanja de Weerd, Fred C.G.J. Sweep, John A. Foekens, Paul N. Span, John W.M. Martens, Henrik J. Ditzel,